JC03 Rec'd PCT/PTO 1 4 NOV2004

Patent Application Attorney Docket No. PC27365

Thereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22,113-1450 on this 11th day of Novgriber, 2005.

OTPE 10 (Signature of Sperson Affains)

Card A. Seen

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

DANILO GIRIBONE, ET AL.

APPLICATION NO.: 10/540.081

: Examiner: Not Yet Assigned

FILING DATE:

JUNE 16, 2005

Group Art Unit: 1614

TITLE: STABLE ISOTOPE-LABELED CAMPTOTHECIN DERIVATIVES

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450 Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicants, copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicants belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO/FB/A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12). A copy of the International Search Report from counterpart International Application No. PCT/EP03/14801 is also enclosed.

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.A prompt and favorable response is earnestly solicited.

David L. Kershner

Attorney for Applicant(s)

Respectfully submitted

Reg. No. 53,112

Pfizer Inc Patent Department, 5th Floor 150 East 42nd Street New York, NY 10017-5755 (212) 733-0538

Date: November 11, 2005

USERS/DOCS/LA21952/KERSHD/3GKL0H.DOC / 254757 / PC27365 INFO DISCL STMT 11/9/0

et al., "Phar nts", Drug N	FUMBER 6 1 Timacokimimetabolisi	FIL U.S. I	PATENT N PATE 9 9 suding Au	NT DOG	E 16, 2005 MENTS DATE CUMENTS DATE 7/8/04 2/29/01 de, Date, Proposition of trinotection	COUNTRY PCT PCT PCT entinent Pages, an (CPT-11) follow		161- SUBCIASS SUBCIASS	FLING APPROI	PRIATI
COUMENT NO.	F UMBER 6 1 1 UMENT macokine Metabolis	U.S. I	PATENT N PATE 9 9 suding Au	NT DOC	DATE CUMENTS DATE 7/8/04 2/29/01 le, Date, Parion of Irinotectors	COUNTRY PCT PCT PCT entinent Pages, an (CPT-11) follow	CLASS CLASS	SUBCIASS	FLING APPROI	ATIO
OCUMENT NL 9 2 ER DOCI et al., "Pharits", Drug N	F UMBER 6 1 1 UMENT macokine Metabolis	FOREIG 3 2 S (Inclusions, Medics, Medics, Medics, Medics)	9 9 9 uding Au	9 9 9	DATE CUMENTS DATE 7/8/04 2/29/01 le, Date, Parion of Irinotection	COUNTRY PCT PCT PCT ertinent Pages,	CLASS Etc.)	SUBCLASS	APPROI	ATIC
OCUMENT NL 9 2 ER DOCI et al., "Pharits", Drug N	F 6 1 1 UMENT	3 2 S (Inclusion)	9 9 uding Au	9 9 thor, Title	CUMENTS DATE 7/8/04 2/29/01 Jee, Date, Point of Irinotection	COUNTRY PCT PCT PCT ertinent Pages,	CLASS Etc.)	SUBCLASS	APPROI	ATIO
OCUMENT NL 9 2 ER DOCt tal., "Pharata", Drug N	6 1 UMENT	3 2 S (Inclu	9 9 uding Au	9 9 thor, Title	7/8/04 2/29/01 le, Date, P	PCT PCT ertinent Pages,	Etc.)		YES	Г
g 2 ER DOCU	6 1 UMENT	3 2 S (Inclu	9 9 uding Au	9 9 thor, Title	7/8/04 2/29/01 le, Date, P	PCT PCT ertinent Pages,	Etc.)		YES	Г
g 2 ER DOCU	6 1 UMENT	2 S (Inclu	Juding Au	g thor, Titl	7/8/04 2/29/01	PCT PCT ertinent Pages,	Etc.)		YES	Г
2 ER DOCU	1 UMENT rmacokine Metabolisa	2 S (Inclu	Juding Au	g thor, Titl	2/29/01	ertinent Pages,				N
2 ER DOCU	1 UMENT rmacokine Metabolisa	2 S (Inclu	Juding Au	g thor, Titl	2/29/01	ertinent Pages,				
ER DOCI	UMENT rmacokine Metabolisi	S (Inclu	uding Au	thor, Titi	le, Date, P	ertinent Pages,				
et al., "Phar nts", Drug N	rmacokine Metabolisi	etics, Met	abolism, a	nd Excreti	ion of Irinotec	an (CPT-11) followi				
et al., "Phar nts", Drug N	rmacokine Metabolisi	etics, Met	abolism, a	nd Excreti	ion of Irinotec	an (CPT-11) followi				_
14(4H, 12i harmaceut al., "Stabili ceuticals, 1	H)-dionel, tical Bulle itles of <3 1996, Vol.	, an active tin, Aug. S>H- and 38, No. 8	e metaboli 1995, Vol. <2>H-labe 8, pgs.733 ritium Lab	le of innote 18, No. 8, lled cample 742.	ecan, after a pgs 1114-11 tothecins", Jo	ournal of Labelled Co	ompounds	4C-SN-38 to	rats."	_
., et al., "Ar	ntitumor e	efficacy, p	harmacok	inetics, an		ion of NX211:a low	clearance l	iposomal fo	mulat	ion
l, "Cellular v. 1997, Vo	pharmac ol. 57, No	okinetics . 21, pgs	and cytoto 4811-4816	xicity of c	amptothecin a	and topotecan at no	ormal end ed	cidic pH"., C	encer	_
aranjit A	Aulakh/			DATE C	ONSIDERED	04/29/2	009			_
	v. 1997, V /., et al., "S dioxy-20(S	v. 1997, Vol. 57, No /., et al., "Synthesis dioxy-20(S)-campto	w. 1997, Vol. 57, No. 21, pgs /., et al., "Synthesis of position dioxy-20(S)-camptothecin", J naranjit Aulakh/	w. 1997, Vol. 67, No. 21, pgs 4811-4816 /, et al., "Synthesis of position-specific todioxy-20(8)-camptothecin", Journal of L. naranjit Aulakh/	w. 1997, Vol. 57, No. 21, pgs 4811-4816 /, et al., "Synthesis of position-specific tritium-label didxy-20(S)-camptothecin", Journal of Labelted Congression of Labelted Congr	w. 1997, Vol. 57, No. 21, pgs 4811-4816 /, et al., "Synthesis of position-specific tritium-labeled 20(S)-ca didxy-20(S)-camptothecin", Journal of Labelled Compounds ar arranjit Aulakh/ DATE CONSIDERED	w. 1997, Vol. 57, No. 21, pgs.4811-4816 //, et al., "Synthesis of position-specific tritium-labeled 20(5)-camptothecin, 9-amin didays-20(5)-camptothecin, 3-aurnal of Labelled Compounds and Radiopharmaceu and Compounds and Radiopharmaceu. DATE CONSIDERED 04/29/2	w. 1997, Vol. 97, No. 21, pgs 4811-4816 //, et al., "Synthesis of position-specific tritium-labeled 20(5)-camptothecin, 9-amino-20(6)-cadidioxy-20(5)-camptothecin", Journal of Labelled Compounds and Radiopharmaceuticals, 1993 naranjit Aulakh/ DATE CONSIDERED 04/29/2009	w. 1997, Vol. 57, No. 21, pgs.4811-4816 /, et al., "Synthesis of position-specific tritium-labeled 20(5)-camptohecin, 9-amino-20(6)-camptohecin, diday-20(5)-camptohecin, Journal of Labelled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 2016, "A vial-labeled Compound	I., et al., "Synthesis of position-specific triflum-labeled 20(6)-camplothecin, 9-amino-20(5)-camplothecin, and 10 diday-20(5)-camplothecin*, Journal of Labelled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 9, pt

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

USERS/DOCS/LA21952/KERSHD/SGKJ011: DOC / 254755 / PC27365 INFO DISC CIT - 11/9/05

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CA/